QuantumBio Inc. Announces the Release of Version 5.1.1 of its DivCon Discovery Suite

State College, PA, [February 8, 2012] – QuantumBio Inc., a leader in providing next generation of Structure Based Drug Discovery and Fragment Based Drug Discovery solutions based upon linear scaling, quantum mechanics methods – including the patented QMScore method – has released version 5.1.1 of the DivCon Discovery Suite. In addition to adding support for the newest version of the Molecular Operating Environment (MOE) platform from Chemical Computing Group, Inc. (CCG), the following significant improvements have been made.

For download information, please contact moc.c1337307568nioib1337307568mutna1337307568uq@se1337307568las1337307568

New Features (since v5.0):

  • MOE/DivCon: For pairwise energy decomposition heatmap, sequence alignment within the MOE/DivCon interface has been completely overhauled in order to use CCG’s sequence alignment tool.
  • MOE/DivCon: Multitasking within the MOE/DivCon graphical user interface runs freely while DivCon is running in the background. Improved QM convergence reporting to MOE’s svl window.
  • File Processing: Included HDFView and QBReporter applications for opening and processing *.h5 output files, and translating them to Excel or OpenOffice spreadsheet files. Reported results include QMScores, partial charges, gradients, and significant events. QBReporter requires that OpenOffice 3.3.0 or greater from OpenOffice.org has been installed and that the resulting soffice executable is available within the command line $PATH.
  • Core: Support for Sun Grid Engine (SGE) in addition to the Portable Batch System (PBS). Note: SGE requires that its parallel environment (PE) be activated in order to run multiprocessing jobs.
  • Core: Shipment of both 32bit and 64bit native versions of all Linux binaries in order to account for larger memory, disk, etc (and therefore larger target/ligand structures).
  • Core: Separation of QuantumBio-specific software from 3rd party binaries (such as mpirun) in order to allow for parallel installations of the same.
  • MOE/DivCon: Inclusion of ${QBHOME}/bin/qbmoe and ${QBHOME}/bin/qbmoebatch to run system-installed MOE and MOE/batch with QuantumBio-required options.
  • MOE/DivCon: Addition of support for MS Windows7 (64bit) both for preparation and analysis. Prepared structures can then be characterized with qbmoebatch on Linux or Mac OS X.
  • Documentation: Completely updated on-line documentation for MOE/DivCon.
  • MOE/DivCon: Entirely redesigned and streamlined dialogs, and improved integration with standard MOE structure preparation and analysis tools.
  • MOE/DivCon: Patented QMScore integrated as an available score function for MOE tools including Dock, Scaffold Replacement, BREED, etc.
  • DivCon: Support for additional input file formats including cif, sdf, and h5.
  • DivCon: Command line –help switch improved to provide default settings, simplified switches, and clarified help.

Bug Fixes (since v5.0):

  • Space in working directory name caused crash. MOE interfaces now access files located under folders with spaces in names.
  • Unknown errors or errors and exceptions were not being reported to user. Exception handling upgraded and now working properly for release mode builds. Improved feedback to user provided.
  • In MOE/DivCon PWD heatmap, unknown residues were reported even when known. Associated incorrect alignment. The new MOE-based sequence alignment method eliminates this situation from arising. As long as MOE understands the sequence and correctly aligns the structure, the heatmap will be correct.
  • “NANs,” memory explosions and stoppage of runs occurred on certain runs. In previous releases, residues were then sent in duplicate to DivCon and with identical coordinates. This problem has been fixed.
  • Unable to select ligand for treatment. User can now designate the ligand using MOE “Choose Ligand” button.
  • Unable to run system-installed mpirun instead of QuantumBio provided mpirun for non-QuantumBio software. These 3rd party binaries are now “buried” within the install and they are only loaded into the ${PATH} at runtime when the user chooses to run a QuantumBio software.
  • Unable to execute multiple QMScore jobs serially or single jobs on a single processor. Fixed.
  • During QMScore some ligands did not converge as prior versions had. Fixed.
  • PDB, MOL2 and SDF parsing errors from input from other programs. Fixed.
  • Intermediate h5 files were large. Data stored in intermediate files has been abbreviated and compressed.
  • Remove some/all of the hard coded paths within MOE/DivCon mdb’s. These paths corrected so one user can send an mdb to another user to be used without editing these paths and updating the mdb.
  • Failure on single protein in mdb/h5 files. Fixed.
  • Failure when ligand was missing from the receptor in MOE/DivCon. Fixed.
  • Renaming MDB file and then clicking update failed in MOE/DivCon. Fixed.

QuantumBio’s DivCon Discovery Suite provides pharmaceutical and biotechnology companies, contract research organizations, and academic groups with the ability to significantly improve accuracy during the virtual screening and lead optimization stages of the drug discovery process. The method is routinely applied to protein/ligand complexes, and recently it has even been applied to larger protein/protein systems. Please visit http://www.quantumbioinc.com for more information on this integration and on cited literature involving QuantumBio’s other technologies.

About QuantumBio Inc.
QuantumBio is a leader in Computer Assisted Drug Design (CADD) and Computer Assisted Molecular Modeling (CAMM), providing a new generation of quantum mechanics solutions to Pharmaceutical, Biotech, Materials and Nanotechnology companies. QuantumBio works with leading pharmaceutical and biotech companies as well as government and academic research organizations to solve problems.

For additional information:

QuantumBio Inc.
Lance M. Westerhoff, PhD
moc.c1337307568nioib1337307568mutna1337307568uq@ec1337307568nal1337307568
www.QuantumBioInc.com

 

Harrisburg event will introduce students to careers in biotechnology

Reprinted from the Thursday, February 2, 2012 edition of  Keystoneedge

Before a student can decide to pursue a career in biotechnology, something has to light a spark of excitement about this growing field.

One goal of the Capital Area Biotechnology Partnershipis to fuel this interest in Harrisburg-area high school students. This group includes several high schools, vocational schools, state agencies and life-sciences companies. The partnership, partially funded by a grant from the state Department of Community and Economic Development, is meant to create clear paths for students to follow through high school and college to jobs in the industry.One highlight of this partnership is its annual Biotechnology Showcase for students in middle school, high school and college. This year it’s set for March 23 at Harrisburg University of Science and Technology. The event will include chances for university students to present their research, activities for younger students in college laboratories (like extracting DNA from a strawberry) and panel discussions in which executives from biotech companies will talk about their businesses and opportunities to work in the growing field.”The students have a chance to see the kind of openings the companies have,” says Leena Pattarkine, who teaches biotechnology the university and directs the partnership. “The material can be taught to them later,” Pattarkine says. “Get them interested now.”

More than 200 students are expected in Harrisburg for the showcase. Pattarkine says that in past years, some have come from as far as Baltimore and Philadelphia.

FDA-approved device to detect macular degeneration raising $2 million

 

MedCity – Philadelphia reports Apeliotus Vision Science gets FDA approval for device to detect macular degeneration. Read the full story here.

http://www.medcitynews.com/2012/01/fda-approved-device-to-detect-macular-degeneration-raising-2-million/?edition=phi

Saladax Biomedical, Inc. Announces the Resignation of Edward L. Erickson as President and Chief Executive Officer

- Kevin M. Harter, former Saladax Executive Chairman, Named Interim CEO-

 Bethlehem, PA, January 27, 2012 – Saladax Biomedical, Inc., a privately-held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Edward L. Erickson, its President and Chief Executive Officer, has resigned due to personal family reasons. His resignation will be effective as an executive officer of Saladax on February 12, 2012, but he will remain a member of the company’s board of directors.

Kevin M. Harter, who is a co-founder and Senior Vice President of the Life Science Greenhouse, a public-private partnership, has been named interim CEO. From 2007 to 2011, Mr. Harter also served as Executive Chairman of Saladax Biomedical, a Life Science Greenhouse portfolio company, where he led successful funding rounds and strategic alliances for the company.

Gregory Critchfield, M.D., Chairman of the Board at Saladax, commented, “The board of directors wishes to express its sincere thanks for Ed’s work, his energy and his commitment in growing Saladax. We are pleased that Ed will remain on the board of directors, as an advisor to the company, with nearly three decades of relevant experience in diagnostics, therapeutics and life science research.The board of directors also extends its gratitude to Kevin for his willingness to assist the company in this interim role. His skill, knowledge and leadership will be invaluable to Saladax.”

Dr. Critchfield continued, “The board of directors is initiating a search to find a permanent CEO. This search will encompass looking within and outside the company, to find the best candidate to continue to execute the company’s strategy and to achieve its promise to become a major provider of personalized medicine products to the medical community for the betterment of patient care.”

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics. The Company’s dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life. The Company’s 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology. The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU). This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems. In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology. In addition the company is finalizing development of its next two oncology drug assays for paclitaxel and docetaxel. Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds. For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.

Media Contact:

Tiberend Strategic Advisors, Inc.

212-827-0020

Andrew Mielach

moc.d1337307568nereb1337307568it@hc1337307568aleim1337307568a1337307568

or

Jason Rando

moc.d1337307568nereb1337307568it@od1337307568narj1337307568

 

Ben Franklin business plan contest to award $50,000 to a promising startup in Central, Northern PA

Thursday, January 12, 2012

The Ben Franklin Technology Partners, an organization that provides money and support services to tech businesses, is sponsoring another business plan contest similar to competitions it has put on over the last decade.

The Big Idea Business Plan Contest, open to entrepreneurs that are already based in a 32-county area or are planning to move there by June, comes with a $50,000 prize for the winner. Judges are looking for promising business ideas in areas like alternative energy, medical devices and nanotechnology. Entrants cannot have received Ben Franklin funding before and must have 50 employees or fewer. The eligible geographic area includes most of the state’s central, northern and western regions.

“It’s really for young, fledgling companies, to give them an opportunity to a) win $50,000 and b) get into the network of economic development service providers,” says Jill Edwards, executive director of the Ben Franklin Venture Investment Forum and Innovation Transfer Network. “We recognize that this region of Pennsylvania has strengths in a whole array of different areas.”

She adds that any company that enters the contest will become known to the Ben Franklin investment network, which opens up other opportunities for funding for help with the process of growing a business.

The contest deadline is Feb. 29 and final judging is expected in June.

Source: Jill Edwards, Ben Franklin Venture Investment Forum /Innovation Transfer Network

Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space

Bethlehem, PA, January 10, 2012 – Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that it has been issued six patents within the last 12 months, bringing the company’s total to 15 issued U.S. patents, all of which contain broad claims in the immunoassay space.  The issued patents are as follows:

·        Busulfan Immunoassay: U.S. Patent No. 7,893,220

·        Stabilized Standards for Busulfan Immunoassay: U.S. Patent #8,039,220

·        Doxorubicin Immunoassay: U.S. Patent No. 8,053,205

·        Imatinib Immunoassay: U.S. Patent No. 8,076,097

·        Doxorubicin Immunoassay: U.S. Patent No. 8,084,586

·        Resperidone Immunoassay: U.S. Patent No. 8,088,594

“The issuance of these patents in the U.S. positions Saladax as the leader in chemotherapy dose management and we believe that Saladax has been issued more patents in the therpeutic dose management (TDM) space than any other diagnostic company,” said Salvatore J. Salamone, founder and CSO of Saladax.  “Of particular note, our patent for Resperidone marks a significant milestone for Saladax as this is our first patent in the CNS field.”

About My5-FU™

Saladax’s first commercially available test for innovative dose management, My5-FU, measures levels of 5-flourouracil (5-FU), a widely prescribed chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and other side effects.

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company’s dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company’s 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems.  In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology. In addition the company is finalizing development of its next two oncology drug assays for paclitaxel and docetaxel.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.

Saladax Biomedical,  Edward L. Erickson, President and Chief Executive Officer, moc.x1337307568adala1337307568s@nos1337307568kcire1337307568e1337307568

Media Contact: Tiberend Strategic Advisors, Inc., 212-827-0020, Andrew Mielach, moc.d1337307568nereb1337307568it@hc1337307568aleim1337307568a1337307568    or Jason Rando,  moc.d1337307568nereb1337307568it@od1337307568narj1337307568

 

Tax Incentives Available for Businesses Hiring People with Disabilities

Did you know? Companies that hire people with disabilities may be eligible for tax credits or deductions. Pennsylvania offers a variety of tax credits and programs for large, medium and, yes, even small businesses. For more information, visit WorksForMe-PA.org or call the Works for me hotline at 1-877-268-9894.

Ben Franklin Technology Partners’ $50,0000 Big Idea Business Plan Contest is Back!

The Ben Franklin Venture Investment Forum in partnership with the Ben Franklin Technology Partners of Central and Northern PA announced that the BIG IDEA Business Plan Contest is back! A grand prize of $50,000 will be awarded to one tech-based startup company! Entrepreneurs can visit http://www.cnp.benfranklin.org/ and click on the contest button for additional information. The deadline for applications is February 29, 2012.

Malvern’s Deltagen BioServices Launches $2.3M Offering – cbl

By Richard Rabicoff

MALVERN, Pa. - Deltagen BioServices, Inc. has launched an offering of $2.3 million, raising $1.3 million from 12 investors.

According to a company statement, the funding is a secured bridge loan, led by Life Sciences Green House of Central Pennsylvania. Proceeds will be used to fund operations.

Named in the related SEC filing were President Paula MacDonald, and directors Warren Bogard, Hemispherx Biopharma; Kevin Harter, Life Sciences Greenhouse; David McLachlan, Skyworks Solutions, Inc.; and Thomas Penn, Meridian Venture Partners.

Deltagen BioServices is a wholly-owned subsidiary of Deltagen, Inc. (Pink Sheets:DGEN), a provider of drug discovery tools to the biopharmaceutical industry.

Deltagen BioServices recently completed facility commissioning and validation of equipment, systems and assays, but due to repair issues its commercial operations have been delayed and the company faces rent payment issues at the Malvern, Pa. facility.

SEC filing: http://tinyurl.com/7ryk3q4

DCED Secretary Announces Allocation of Federal Funds to Support Small Business Job Creation

December 21, 2011 -  Harrisburg – Department of Community and Economic Development (DCED) Secretary C. Alan Walker announced today the  allocation of $29.2 million of funding from the United States Department of the Treasury’s State Small Business Credit Initiative (SSBCI) to economic, community and technology development partners throughout the  commonwealth.

“The  Corbett administration is committed to supporting our small  businesses and the best way to do that is by partnering with the private sector to maximize resources,” said Walker. “I am proud to say that Pennsylvania is the only state in the nation that requested proposals from our local partners with a goal of maximizing investment and supporting the best projects. This initiative will result in significant small business job creation across the  state.”

After receiving notification from the Treasury department of the  SSBCI program, DCED reached out to its development partners throughout the state to determine what funding gaps currently existed for small  businesses. As a result, the department determined that the best approach was to give the organizations, which interact with small  businesses every day, the opportunity to apply for a portion of the funding.  By partnering with the private sector to support local  projects -rather than using the entire funding to supplement existing state programs -the impact of  job creation and private investment in the commonwealth will be much greater.

The SSBCI program is part of the Small  Business Jobs Act that was signed into law in September, 2010. Funding  will  be allocated to 12 entities to support statewide and regional job generating programs, early-stage technology companies and Community Development Financial Institutions.

Secretary Walker  was joined today by State  Senator John Gordner and representatives of the organizations that will  be receiving the SSBCIfunding.

“Small businesses are an integral part of Pennsylvania’s economy, accounting for over  98 percent of the  state’s employers and nearly 50 percent of its  private-sector employment,” said Gordner.  “I applaud DCED for taking a business-minded approach and reaching out to address and enhance small business’ capital needs.”

For more information about economic development initiatives in Pennsylvania, call 1-866-466-3972 or visit newPA.com.

Media contact:
Steven Kratz, DCED; 717-783-1132

Editor’s Note: Allocation of SSBCI Funds

Altoona-Blair County Development Corporation (ABCD Corp)  is a DCED certified  economic development corporation, serving  nineteen  counties  in south Central and Western Pennsylvania.   The organization will use the funding  to create the “Innovate PA fund”- a program designed  to provide  low-interest loans to meet the financing  needs of small businesses that  are presently not being  met by public and private  lenders.  ABCD Corp. will receive  $2 million of SSBCI funding, projected to finance a minimum of 12 loans and create  at least 80 jobs.

Ben Franklin Technology Development Partners (BFTDA) and the Life Science  Greenhouses (LSG) are non-profit economic  development intermediaries created  by the commonwealth to accelerate innovation, economic  growth  and jobs in the state’s  high technology economy.  The BFTDA and LSG programs will receive $5 million of SSBCI funding, projected to finance 17 early-stage Pennsylvania technology companies, create 163 high-paying jobs and attract over $50 million of private  financing.

Bridgeway Capital is a DCED Community Development Financial Institution that serves businesses and nonprofits in Western Pennsylvania.   The organization will receive $2 million in SSBCI funding to continue making entrepreneur and growth capital  loans, and loans to nonprofits. The funding  is projected to finance 510 loans, create nearly 2,600  jobs and attract over $97 million  in private financing.

Central Bradford Progress Authority (CBPA) is a DCED certified area loan organization covering  the counties  of Bradford, Susquehanna, Sullivan and Wyoming. The organization will utilize  its 18 years of economic development lending experience to provide capital to small business in their region and those specifically tied to Marcellus Shale.  CBPA will receive $1 million of  SSBCI funding, projected to finance 10 loans and create 150 jobs.

Community First Fund is a DCED certified Community Development Financial Institution that  serves 13 counties  in central and eastern Pennsylvania.   Community First will receive $2 million in SSBCI funding to provide loans to underserved small businesses with impaired access to credit during  the current recession.  The funding will be used to create an additional $19 million in private economic  investments, and is projected to finance 246 loans and create  1,850  jobs.

The Economic Opportunities Fund {EOF) of the Womens Opportunity Resource Center is a Community Development Financial Institution that serves the five­ county Philadelphia region.   The organization will utilize its 12 years of economic development experience to continue  providing low-income women and minorities with startup capital.   EOF will receive $262,500 in SSBCI funding,  projected to finance 39 loans and create 26 jobs.

Northside Community Development Fund (NCDF) is a DCED certified Community Development Financial Institution that provides financing for small business and real estate  projects on Pittsburgh’s Northside. The funding will be used to make loans to underserved,  low-income census neighborhoods.  NCDF will receive $250,000 in SSBCI funding, projected to finance 5 loans, and create 13 jobs.

Pennsylvania Industrial Development Corporation (PIDC) is private nonprofit corporation with a 53 year history of stimulating economic development by leveraging financing and real estate resources that attract,  retain and grow businesses in Philadelphia.   PIDC will receive $2 million of SSBCI funding, projected to support  a minimum of four projects and create at least 40 jobs.

The Progress Fund is a DCED certified Community Development Financial Institution serving  39 counties in Western and Northern Pennsylvania.   The organization will receive $2 million of SSBCI funding  to continue  providing capital for rural, tourism-related projects. The funding  is projected to finance  40 loans, and create 500 jobs.

The South  Eastern Economic  Development Corporation (SeedcoPA) is a DCED certified economic development corporation serving  Chester County.  The organization will serve as the Credit Support Program for the SSBCI-funded and approved Pennsylvania Regional Revolving  Loan Fund (PRRLF).  The PRRLF will include many of the Southeastern Pennsylvania economic development councils and local and regional  banks.  These entities will contribute capital to the PRRLF which will be used as a source of funds for the loans. SeedcoPA will receive $2 million of SSBCI funding, projected to support  a minimum of 40 projects  and create at least 186 jobs.

SEDA-COG is a DCED certified economic development corporation serving 11 counties in Central Pennsylvania.   The organization will use the funding to provide small businesses loans to for-profit companies involved in promoting technology and communications, and businesses involved in Marcellus and Utica Shale activities.  SEDA-COG will receive $1 million of SSBCI funding, projected to support 10 loans and create at least 420 new jobs.

The Pennsylvania Machinery and  Equipment Loan Fund  (MELF) is administered by DCED and designed to attract economic growth by providing low­ interest loan financing for a portion of the cost of machinery and equipment purchases. To be eligible  for MELF, businesses  must commit to creating or retaining jobs. MELF will receive $9 million of SSBCI funding, projected to support a minimum of 13 projects and create at least 828 jobs.
###

  • The Funding Process

    The Funding Process

    The Life Sciences Greenhouse of Central Pennsylvania provides investment funding up to $1 million in milestone-driven convertible…

    Read more
  • Our Resource Center

    tomb2

    It’s a familiar scenario. You hear about a discovery that could lead to the cure for this disease or that debilitating…

    Read more
  • The 'PA' in LSGPA

    tomb3

    The Life Sciences Greenhouse of Central Pennsylvania’s 42-county service area contains more than 60 institutions of higher …

    Read more